Nina P Paynter

List of Publications by Year
in descending order

34 papers	2,781 citations	430754 18 h-index	414303 32 g-index
34 all docs	34 docs citations	34 times ranked	5224 citing authors

#	Article	IF	Citations
1	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	13.9	886
2	Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women. JAMA - Journal of the American Medical Association, 2010, 303, 631.	3.8	320
3	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
4	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Molecular Psychiatry, 2015, 20, 647-656.	4.1	235
5	Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3. Annals of Internal Medicine, 2009, 150, 65.	2.0	225
6	Adverse Effects of Low-Dose Methotrexate. Annals of Internal Medicine, 2020, 172, 369.	2.0	126
7	Performance of reclassification statistics in comparing risk prediction models. Biometrical Journal, 2011, 53, 237-258.	0.6	97
8	Primary Prevention With Statin Therapy in the Elderly. Circulation, 2017, 135, 1979-1981.	1.6	97
9	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. JAMA Internal Medicine, 2018, 178, 1231.	2.6	58
10	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	3.0	53
11	Prediction of Incident Hypertension Risk in Women with Currently Normal Blood Pressure. American Journal of Medicine, 2009, 122, 464-471.	0.6	52
12	Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women. Clinical Chemistry, 2011, 57, 1178-1187.	1.5	42
13	Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. European Journal of Preventive Cardiology, 2015, 22, 519-526.	0.8	41
14	A Bias-Corrected Net Reclassification Improvement for Clinical Subgroups. Medical Decision Making, 2013, 33, 154-162.	1.2	34
15	Cardiovascular Risk Prediction in Diabetic Men and Women Using Hemoglobin A<sub>1c</sub> vs Diabetes as a High-Risk Equivalent. Archives of Internal Medicine, 2011, 171, 1712.	4.3	33
16	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. Circulation Research, 2016, 118, 607-619.	2.0	28
17	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. Seminars in Arthritis and Rheumatism, 2017, 47, 133-142.	1.6	26
18	Comments on â€˜Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersâ€™ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg. Statistics in Medicine, 2012, 31, 93-95.	0.8	20

#	Article	IF	Citations
19	Metabolomic profiles associated with all-cause mortality in the Women's Health Initiative. International Journal of Epidemiology, 2020, 49, 289-300.	0.9	20
20	Cardiovascular Disease Risk Prediction in Women: Is There a Role for Novel Biomarkers?. Clinical Chemistry, 2014, 60, 88-97.	1.5	19
21	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatology, 2020, 2, 697-704.	0.9	18
22	Metabolic signatures associated with Western and Prudent dietary patterns in women. American Journal of Clinical Nutrition, 2020, 112, 268-283.	2.2	18
23	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1225-1231.	2.9	11
24	Clinical risk reclassification at 10 years. Statistics in Medicine, 2017, 36, 4498-4502.	0.8	10
25	Estimating the receiver operating characteristic curve in matched case control studies. Statistics in Medicine, 2019, 38, 437-451.	0.8	8
26	Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group. BMJ, The, 2016, 354, i4450.	3.0	6
27	Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. American Journal of Cardiology, 2016, 118, 49-55.	0.7	5
28	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagnostic and Prognostic Research, 2018, 2, .	0.8	5
29	Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women. Circulation Genomic and Precision Medicine, 2020, 13, e002977.	1.6	4
30	Abstract P021: Performance Of Pooled Cohort Equations And MESA Risk Score Across Race/Ethnicity And Socioeconomic Status To Estimate 10-year Cardiovascular Risk In Diverse New England Cohort. Circulation, 2022, 145, .	1.6	4
31	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology, 2021, 60, 2963-2968.	0.9	3
32	Does the 9p21 Genetic Variant Have a Role in Cardiovascular Risk Prediction?. Current Cardiovascular Risk Reports, 2011, 5, 159-164.	0.8	1
33	Cardiovascular Risk Prediction. Circulation Research, 2017, 121, 1032-1033.	2.0	0
34	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application. ACR Open Rheumatology, 2020, 2, 269-275.	0.9	0